A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 20, 2022

Primary Completion Date

September 3, 2025

Study Completion Date

September 3, 2025

Conditions
Sickle Cell DiseaseThalassemia
Interventions
DRUG

Etavopivat tablets

Etavopivat 400 mg once daily

Trial Locations (16)

1434

Hospital Nini, Tripoli

10065

Weill Medical College of Cornell University, New York

12613

Cairo University, Cairo

27858

East Carolina University, Greenville

45229

[Legal] Children's Hospital Medical Center dba Cincinnati Children's, Cincinnati

90027

[Legal] Children's Hospital Los Angeles, Los Angeles

92868

[Legal] Children's Hospital of Orange County on behalf of CHOC Children's Hospital of Orange County, Orange

94609

UCSF Oakland Benioff ChildHosp, Oakland

4241317

Abu El-Reesh El-Mounira Children University Hospital, Cairo, Egypt

M5G 1X8

The Hospital for Sick Children, Toronto

M5G 2C4

University Health Network - Toronto General Hospital, Toronto

H3T 1C5

CHU Sainte-Justine Mother and Child University Hospital, Montreal

RGWX 4CG

Chronic Care Center, Baabda

E1 1FR

Barts Health NHS Trust - The Royal London Hospital, London

W12 0HS

Imperial College Healthcare NHS Trust - Hammersmith Hospital, London

M13 9WL

Manchester University NHS Foundation Trust, Manchester

Sponsors
All Listed Sponsors
lead

Forma Therapeutics, Inc.

INDUSTRY